Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The vaccine in the APPROACH study, which led to the Imbokodo and forthcoming Mosaico trails, prompted a robust immune response.
The investigational, injectable, long-acting antiretroviral is a potential new option for those with multidrug resistance.
Currently, Gilead Sciences’ HIV regimen is not approved to treat drug-resistant virus.
An NIH-sponsored peer-recruitment study is part of a larger push to figure out how to drive up the viral suppression rate in the U.S.
Pharmacists oversaw the delivery of hepatitis C treatment in a recent study.
The program was associated with an impressive rise in viral suppression rates.
Researchers have sought to pinpoint why HIV doubles cardiovascular disease risk.
The Mosaico study will enroll gay and bisexual men and transgender people at significant risk for the virus.
HIV-positive people who underwent surgery to remove early lung cancer fared as well as HIV-negative people.
Generalized anxiety disorder is associated with lower rates of HIV treatment, adherence to treatment and viral suppression.
A new analysis of the global START trial found that health outcomes were better for those starting treatment within six months.
After almost a decade on antiretroviral therapy, half of study participants still had HIV in immune cells in their brain and spinal fluid.
Electronic prompts for clinicians to recommend Truvada to people at risk for HIV could help increase PrEP’s impact.
Researchers compared outcomes between babies born to HIV-positive mothers exposed to antiretrovirals and those who were not.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.